ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0486

Associations Between Frailty and Incident Cancer and Cancer-related Mortality in Veterans with Rheumatoid Arthritis
Abstract Number: 2694

Associations Between Immune Checkpoint Molecules and Nasal Microbiome in ANCA-associated Vasculitis
Abstract Number: 2061

Associations Between Intramyocellular Lipid and Muscle Function in Patients with Osteoarthritis
Abstract Number: 2289

Associations Between Protein Quantitative Trait Loci and Risk of Primary Sjögren’s Syndrome: A Mendelian Randomization Study
Abstract Number: 1006

Associations Between Rheumatic Diseases and Mental Health Disorders
Abstract Number: 0192

Associations Between Social Determinants of Health and Acute Care Use Among Individuals with Lupus, Rheumatoid Arthritis and Osteoarthritis in the All of Us Research Program
Abstract Number: 0196

Associations Between Systemic Lupus Erythematosus (SLE) and the Social Vulnerability Index (SVI)
Abstract Number: 1572

Associations Between the Gut Microbiota, Ultra-Processed Food Intake, and Gastrointestinal Tract Symptoms in Patients with Systemic Sclerosis
Abstract Number: 2616

Associations of Circulating Inflammatory Cytokines with Long COVID Among Patients with Systemic Autoimmune Rheumatic Diseases
Abstract Number: 0978

Associations of Fire Smoke and Other Pollutants with Incident Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Interstitial Lung Disease
Abstract Number: 1424

Associations of Human Leukocyte Antigens (HLA) Class II with Interstitial Lung Disease (ILD) in Patients with Systemic Autoimmune Rheumatic Diseases (SARDs). A Prospective Study in Sequential Patients with SARD-ILD
Abstract Number: 0800

Associations of Rheumatoid Arthritis Polygenic Risk with Age at Onset, Serostatus, and Interstitial Lung Disease
Abstract Number: 0047

Asthma Is Associated with Increased Serum IgA Antibodies to Citrullinated Peptide Antigenscompared to Healthy Controlsin Discovery and Validation Cohorts
Abstract Number: 2411

Attainment of Complete Renal Response in Patients with Active Lupus Nephritis: A Multi-Center Cohort Study
Abstract Number: 2435

Attainment of Remission, Use of Immunomodulatory/suppressive Agents and Gradual Dose Tapering May Facilitate Flare-free Withdrawal of Glucocorticoids in Patients with Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].